# Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

> **NCT01628913** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumors (pNET)

## Interventions

- **DRUG:** BEZ235
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01628913
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment.
- **Last updated:** 2016-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628913, "Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01628913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*